Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any autosomal recessive non-syndromic intellectual disability in which the cause of the disease is a mutation in the LINS1 gene.
Features include always present findings: Microcephaly, Absent speech, Global developmental delay, and Midface retrusion and others; and common findings: Low muscle tone (hypotonia), Depressed nasal bridge, Persistent head lag, and Failure to thrive and others.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 5 | Absent speech, Global developmental delay, Depressed nasal bridge |
Growth and development | 2 | Failure to thrive, Growth delay |
Head and neck | 1 | Microcephaly |
Muscles | 1 | Low muscle tone (hypotonia) |
LINS1 encodes lines homolog 1 (757 aa). Highest expression in Cells EBV-transformed lymphocytes (8.7 TPM) and Thyroid (8.2 TPM).
Intellectual disability, autosomal recessive 27 is associated with mutations in the LINS1 gene on chromosome 15.
LINS1 is classified as a druggable target with score 0.0.
Genetic testing for LINS1 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for intellectual disability, autosomal recessive 27 has been reported in the published literature.
Phenotype severity distribution: 5 always present features, 6 common features.
No clinical trials have been registered for intellectual disability, autosomal recessive 27.
21 publications have been identified in PubMed for intellectual disability, autosomal recessive 27. Research spans Case Report / Case Series (24%), Basic Science / Preclinical (19%), and Diagnostic / Biomarker (14%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 5 | 24% |
Laboratory research | 4 | 19% |
Testing and diagnosis research | 3 | 14% |
Research summaries | 3 | 14% |
Clinical study results | 2 | 10% |
New treatment approaches | 2 | 10% |
Other research | 1 | 5% |
Disease patterns and progression | 1 | 5% |
Alimoradi E (2026). [PMID: 41656075](https://pubmed.ncbi.nlm.nih.gov/41656075/). *Mol Genet Genomic Med*. [Case Report / Case Series]
Binsfeld R (2026). [PMID: 41596680](https://pubmed.ncbi.nlm.nih.gov/41596680/). *Int J Mol Sci*. [Gene Therapy / Novel Therapeutics]
Cesur Baltacı HN (2026). [PMID: 41064050](https://pubmed.ncbi.nlm.nih.gov/41064050/). *Mol Syndromol*. [Case Report / Case Series]
Bylstra Y (2025). [PMID: 41453871](https://pubmed.ncbi.nlm.nih.gov/41453871/). *NPJ Genom Med*. [Diagnostic / Biomarker]
Chen J (2025). [PMID: 41188742](https://pubmed.ncbi.nlm.nih.gov/41188742/). *BMC Pediatr*. [Case Report / Case Series]
Harding CO (2025). [PMID: 40411344](https://pubmed.ncbi.nlm.nih.gov/40411344/). *Genet Med*. [Clinical Trial Publication]
Akar HT (2025). [PMID: 39953904](https://pubmed.ncbi.nlm.nih.gov/39953904/). *J Pediatr Endocrinol Metab*. [Epidemiology / Natural History]
Hashmi HB (2025). [PMID: 41452392](https://pubmed.ncbi.nlm.nih.gov/41452392/). *Neurogenetics*. [Diagnostic / Biomarker]
Baker M (2025). [PMID: 40700090](https://pubmed.ncbi.nlm.nih.gov/40700090/). *Vision (Basel)*. [Review / Meta-Analysis]
Shah AWA (2025). [PMID: 40813497](https://pubmed.ncbi.nlm.nih.gov/40813497/). *Mol Biol Rep*. [Basic Science / Preclinical]
Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 11:15 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center